All In Biotech

Drug Trial Radar · NCT00105313

Study to Evaluate MEDI-507 in Patients With CD2-Positive Lymphoma/Leukemia

A Phase I Open-Label Dose Escalation Study to Evaluate MEDI-507 in Patients With CD2-Positive Lymphoma/Leukemia

Last checked: Nov 20, 2026Latest source record: Jun 14, 2007 (this record)Source: ClinicalTrials.govMethods & limitations

Terminated

Status

Terminated

Enrollment

80

Planned (sponsor's estimate)

Start

Feb 2005

Primary completion

Not stated

Sponsor

Lead sponsor
MedImmune LLCAstraZeneca (AZN)
Sponsor type
Industry
First posted
Mar 14, 2005

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Single group
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

For primary objectives, we will determine the MTD and examine clinical responses and immune cell populations to determine an OBD, and describe the safety and tolerability of MEDI-507. For the secondary objectives we will look at the antitumor activity of MEDI 507, PK, serum concentrations, and immunogenicity of MEDI-507, as well as time courses of depletion and recovery of CD2 positive and total T-Cell populations.

Conditions

  • Lymphoma
  • Leukemia
  • Cancer

Interventions

  • MEDI-507Drug

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. To determine the maximum tolerated dose (MTD) or the optimal biological dose
  2. (OBD) of MEDI-507 based on safety and tolerability of MEDI-507 in patients with
  3. CD-2 positive lymphoproliferative disorders.

Locations

11 sites in 1 country. Site status is shown where the registry gives one.

  • USC/Norris Cancer Center

    Los Angeles, California

  • Yale Cancer Center

    New Haven, Connecticut

  • Georgetown University Medical Center, Lombardi Comprehensive Cancer Center

    Washington D.C., District of Columbia

  • H. Lee Moffitt Cancer Ctr & Research Institute Div of Hem/Onc

    Tampa, Florida

  • University of Maryland School of Medicine, Greenebaum Cancer Center

    Baltimore, Maryland

  • Tufts New England Medical Center

    Boston, Massachusetts

  • Washington University

    St Louis, Missouri

  • Nevada Cancer Institute

    Las Vegas, Nevada

  • Wake Forest University Health Sciences

    Winston-Salem, North Carolina

  • Kimmel Cancer Center, Thomas Jefferson University

    Philadelphia, Pennsylvania

  • M.D. Anderson Cancer Center

    Houston, Texas

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.